197 related articles for article (PubMed ID: 19223556)
1. Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity.
Arora S; Wang XI; Keenan SM; Andaya C; Zhang Q; Peng Y; Welsh WJ
Cancer Res; 2009 Mar; 69(5):1910-5. PubMed ID: 19223556
[TBL] [Abstract][Full Text] [Related]
2. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
[TBL] [Abstract][Full Text] [Related]
3. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
4. LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity.
Qin M; Peng S; Liu N; Hu M; He Y; Li G; Chen H; He Y; Chen A; Wang X; Liu M; Chen Y; Yi Z
J Pharmacol Exp Ther; 2015 Dec; 355(3):473-83. PubMed ID: 26377911
[TBL] [Abstract][Full Text] [Related]
5. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
6. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
7. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.
Liu Z; Zhou Z; Tian W; Fan X; Xue D; Yu L; Yu Q; Long YQ
ChemMedChem; 2012 Apr; 7(4):680-93. PubMed ID: 22311585
[TBL] [Abstract][Full Text] [Related]
9. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
[TBL] [Abstract][Full Text] [Related]
10. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
Meng F; Cai X; Duan J; Matteucci MG; Hart CP
Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
[TBL] [Abstract][Full Text] [Related]
11. Leiodermatolide, a novel marine natural product, has potent cytotoxic and antimitotic activity against cancer cells, appears to affect microtubule dynamics, and exhibits antitumor activity.
Guzmán EA; Xu Q; Pitts TP; Mitsuhashi KO; Baker C; Linley PA; Oestreicher J; Tendyke K; Winder PL; Suh EM; Wright AE
Int J Cancer; 2016 Nov; 139(9):2116-26. PubMed ID: 27376928
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
Wang F; Yang Z; Liu Y; Ma L; Wu Y; He L; Shao M; Yu K; Wu W; Pu Y; Nie C; Chen L
Bioorg Med Chem; 2015 Jul; 23(13):3337-50. PubMed ID: 25937236
[TBL] [Abstract][Full Text] [Related]
13. (Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies.
Reddy MV; Akula B; Cosenza SC; Lee CM; Mallireddigari MR; Pallela VR; Subbaiah DR; Udofa A; Reddy EP
J Med Chem; 2012 Jun; 55(11):5174-87. PubMed ID: 22587519
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site.
Liu YN; Wang JJ; Ji YT; Zhao GD; Tang LQ; Zhang CM; Guo XL; Liu ZP
J Med Chem; 2016 Jun; 59(11):5341-55. PubMed ID: 27172319
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents.
Tian C; Chen X; Zhang Z; Wang X; Liu J
Eur J Med Chem; 2019 Dec; 183():111679. PubMed ID: 31541870
[TBL] [Abstract][Full Text] [Related]
16. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
[TBL] [Abstract][Full Text] [Related]
17. 2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition.
Romagnoli R; Kimatrai Salvador M; Schiaffino Ortega S; Baraldi PG; Oliva P; Baraldi S; Lopez-Cara LC; Brancale A; Ferla S; Hamel E; Balzarini J; Liekens S; Mattiuzzo E; Basso G; Viola G
Eur J Med Chem; 2018 Jan; 143():683-698. PubMed ID: 29220790
[TBL] [Abstract][Full Text] [Related]
18. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
[TBL] [Abstract][Full Text] [Related]
19. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
[TBL] [Abstract][Full Text] [Related]
20. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
